Pharma Companies Have Improved How They Engage with Healthcare Providers During COVID-19, Finds New Research from Accenture
NEW YORK; Aug. 10, 2020 – As a result of COVID-19, pharmaceutical companies are changing how they engage with healthcare providers (HCPs), which is helping HCPs better serve patients, according to findings of an Accenture (NYSE: ACN) survey of 720 general practitioners, oncologists, cardiologists and immunologists globally.
August 10, 2020
Accenture Named a Leader in Everest Group’s Medical Devices Digital Services PEAK Matrix® Assessment 2020
NEW YORK; July 13, 2020 – Accenture (NYSE: ACN) is positioned as a Leader in medical devices digital services in a new report from independent research firm Everest Group.
July 13, 2020
Patients Want to Continue to Use Virtual Care Even After the Pandemic Ends, Accenture Survey Finds
NEW YORK; July 9, 2020 – Patients have embraced virtual care and communications at very high rates as a result of COVID-19 and nine out of 10 reported the quality of care was as good or better than before, according to findings of an Accenture (NYSE: ACN) survey of 2,700 oncology, cardiology, or immunology patients globally.
July 09, 2020
Accenture Named a Leader in Life Sciences Operations by Independent Research Firm Everest Group
NEW YORK; Feb. 28, 2020 – Accenture (NYSE: ACN) is positioned as a leader in life sciences operations services in a new report from independent research firm Everest Group.
February 28, 2020
Accenture and Google Cloud Collaborate to Help Life Sciences Companies Advance the Discovery, Development and Delivery of Innovative Therapies
NEW YORK and SUNNYVALE; Jan. 28, 2020 – Accenture (NYSE: ACN) and Google Cloud (NASDAQ: GOOG, GOOGL) today announced that Google Cloud will be the cloud technology provider for Accenture’s INTIENT™ life sciences industry platform.
January 28, 2020
UCB and Accenture Collaborate to Accelerate Data Processing and Help Improve Patient Safety
NEW YORK; Dec 16, 2019 – Accenture (NYSE:ACN) and UCB, a global biopharmaceutical company, have collaborated to build a safety solution based on Accenture’s INTIENT™ Pharmacovigilance to accelerate processing of individual patient safety case reports. This will help UCB uncover patient safety impacts from existing treatments and better manage the risks of new drugs and services.
December 16, 2019
Accenture Named a Leader in Life Sciences Digital Services by Independent Research Firm, Everest Group
NEW YORK; Dec. 10, 2019 – Accenture (NYSE: ACN) has been named a Leader in life sciences digital services in a new report from Everest Group, a leading independent research firm.
December 10, 2019
Ajinomoto and Accenture to Establish Joint Venture to Help Drive Ajinomoto’s Operational Transformation
TOKYO; Nov. 7, 2019 – Ajinomoto Co., Inc. and Accenture (NYSE: ACN) have agreed to establish a joint venture in Japan to help the food and biotech company accelerate its operational transformation.
November 07, 2019
Accenture to Help Santen Pharmaceutical Build a Global Intelligent Enterprise Platform on SAP® S/4HANA® to Drive Its Digital Transformation
TOKYO; Oct. 30, 2019 – Accenture (NYSE: ACN) has been selected to help Santen Pharmaceutical Co., Ltd. (Santen), an ophthalmic pharmaceutical company headquartered in Japan, build a global intelligent enterprise platform that will drive the company’s digital transformation.
October 30, 2019
Accenture Announces Collaboration with Bayer to Streamline Drug Development Processes through INTIENT Clinical Platform
NEW YORK; Sept. 16, 2019 – Accenture (NYSE: ACN) has announced a collaboration with Bayer to implement the Accenture INTIENT Clinical platform to help simplify and speed its drug development processes. The platform, which went live at Bayer earlier this year, brings internal and external clinical data together with Oracle cloud-based technologies into a single data management and warehousing platform, creating actionable insights to accelerate drug development and improve patient outcomes.
September 16, 2019